April 22 (Reuters) - The U.S. FDA approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market. (Reporting by Puyaan Singh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.04 USD | -7.97% | -18.42% | +40.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.24% | 4.87B | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.52% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- IBRX Stock
- News ImmunityBio, Inc.
- U.S. FDA approves ImmunityBio's bladder cancer therapy